Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)

Next Previous
Search
Trial Profile

A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms NURTURE
  • Sponsors UCB

Most Recent Events

  • 20 Nov 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov (Parent trial: NCT00899678).
  • 14 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov (Parent trial: NCT00899678).
  • 01 Jul 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov (Parent trial: NCT00899678).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top